{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:49:36Z","timestamp":1791254976071,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, is an effective treatment for chronic plaque psoriasis. Its use is expanding to treat other autoinflammatory conditions; however, acneiform eruptions have been increasingly reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore this, we conducted a systematic review and meta-analysis to quantify the incidence of acneiform eruptions associated with deucravacitinib and compare odds ratios (ORs) vs. placebo, including exploratory analyses by dose and indication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The CENTRAL, Embase and MEDLINE databases were searched for interventional and observational studies. The primary outcome was the incidence of acneiform eruption (including acne, folliculitis, dermatitis acneiform and rosacea). A random-effects meta-analysis was performed to estimate pooled proportions and ORs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 672 records screened, 14 studies met the inclusion criteria, representing 5280 patients treated with deucravacitinib. Overall, 467\/5280 (8.8%) patients developed an acneiform eruption (acne, 71.3%; folliculitis, 23.3%; dermatitis acneiform, 3.2%; and rosacea, 2.1%). Across eight placebo-controlled studies, the pooled incidence was 6.4% [95% confidence interval (CI) 0.05\u20130.09; I2 = 74.9%]. Events occurred in 145\/2539 (5.7%) patients on deucravacitinib vs. 9\/1070 (0.8%) in controls (pooled OR, 4.56; 95% CI 2.28\u20139.12; I2 = 9.4%). Discontinuations for acneiform events were uncommon (n = 7\/3317; 0.2%). Dose-specific and indication-specific analyses suggested higher odds of acneiform events at higher total daily doses and in indications such as psoriasis and inflammatory bowel disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Acneiform eruptions are a frequent cutaneous adverse event with deucravacitinib and occur markedly more often than with placebo, yet rarely lead to discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag286","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:50:12Z","timestamp":1783511412000},"source":"Crossref","is-referenced-by-count":1,"title":["Acneiform eruption with deucravacitinib: a systematic review and meta-analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-0279","authenticated-orcid":false,"given":"James","family":"Gaston","sequence":"first","affiliation":[{"name":"The Royal Children\u2019s Hospital Melbourne , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9877-1730","authenticated-orcid":false,"given":"Andrew","family":"Maxwell","sequence":"additional","affiliation":[{"name":"The Royal Melbourne Hospital , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9651-0707","authenticated-orcid":false,"given":"Hieu Chi","family":"Ha","sequence":"additional","affiliation":[{"name":"School of Medicine, Monash University , Clayton, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-1736","authenticated-orcid":false,"given":"Anna","family":"Antony","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-1432","authenticated-orcid":false,"given":"Francis Yi Xing","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Clayton, VIC ,","place":["Australia"]},{"name":"Skin Health Institute , Carlton, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0246-0484","authenticated-orcid":false,"given":"Senhong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Clayton, VIC ,","place":["Australia"]},{"name":"Skin Health Institute , Carlton, VIC ,","place":["Australia"]},{"name":"Faculty of Medicine Nursing and Health Sciences, Monash University , Clayton, VIC ,","place":["Australia"]},{"name":"Department of Dermatology, Eastern Health , Box Hill, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2026082006263333600_llag286-B1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026082006263333600_llag286-B2","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"2026082006263333600_llag286-B3","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/jcm14051745","article-title":"The expanding therapeutic potential of deucravacitinib beyond psoriasis: a narrative review","volume":"14","author":"Bang","year":"2025","journal-title":"J Clin Med"},{"key":"2026082006263333600_llag286-B4","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026082006263333600_llag286-B5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ajd.14425","article-title":"Acneiform eruption secondary to deucravacitinib: a case series and review of the literature","volume":"66","author":"Tran","year":"2025","journal-title":"Australas J Dermatol"},{"key":"2026082006263333600_llag286-B6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/jocd.13765","article-title":"Psychodermatology of acne: psychological aspects and effects of acne vulgaris","volume":"20","author":"Stamu-O\u2019Brien","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"2026082006263333600_llag286-B7","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026082006263333600_llag286-B8","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026082006263333600_llag286-B9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/cpdd.1308","article-title":"Absolute and relative bioavailability of oral solid dosage formulations of deucravacitinib in humans","volume":"12","author":"Chimalakonda","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026082006263333600_llag286-B10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026082006263333600_llag286-B11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/bjd\/ljae406","article-title":"Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial","volume":"192","author":"Zhang","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026082006263333600_llag286-B12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11096-025-01980-6","article-title":"Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database","volume":"47","author":"Tan","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"2026082006263333600_llag286-B13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082006263333600_llag286-B14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026082006263333600_llag286-B15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026082006263333600_llag286-B16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026082006263333600_llag286-B17","article-title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis","volume":"19","author":"D\u2019Haens","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026082006263333600_llag286-B18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026082006263333600_llag286-B19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105238","article-title":"IL-17\/Th17 pathway is activated in acne lesions","volume":"9","author":"Kelh\u00e4l\u00e4","year":"2014","journal-title":"PLOS ONE"},{"key":"2026082006263333600_llag286-B20","doi-asserted-by":"crossref","first-page":"102303","DOI":"10.1016\/j.xcrm.2025.102303","article-title":"TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation","volume":"6","author":"Tuomela","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026082006263333600_llag286-B21","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14563","article-title":"Activation of Janus kinase signaling pathway in acne lesions","volume":"34","author":"Awad","year":"2021","journal-title":"Dermatol Ther"},{"key":"2026082006263333600_llag286-B22","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"2026082006263333600_llag286-B23","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082006263333600_llag286-B24","article-title":"Association of different cell types and inflammation in early acne vulgaris","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"2026082006263333600_llag286-B25","doi-asserted-by":"crossref","first-page":"16095","DOI":"10.3390\/ijms242216095","article-title":"Inflammation and psoriasis: a comprehensive review","volume":"24","author":"Man","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026082006263333600_llag286-B26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/jid.1958.23","article-title":"An investigation of the biology of the human sebaceous gland","volume":"30","author":"Kligman","year":"1958","journal-title":"J Invest Dermatol"},{"key":"2026082006263333600_llag286-B27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J Dermatol"},{"key":"2026082006263333600_llag286-B28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3\u2005years: an open-label extension of randomized clinical trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026082006263333600_llag286-B29","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/ced\/llae530","article-title":"Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions","volume":"50","author":"Hagino","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026082006263333600_llag286-B30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.36849\/JDD.8955","article-title":"Deucravacitinib with add-on calcipotriene\/betamethasone dipropionate for treating moderate to severe plaque psoriasis","volume":"24","author":"Bagel","year":"2025","journal-title":"J Drugs Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag286\/68740896\/llag286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag286\/68740896\/llag286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:26:44Z","timestamp":1787221604000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag286\/8729324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag286","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"llag286"}}